Physician profile
David D Picklesimer
NPI 1285194258
$1,611.53
in general payments reported to CMS, 2019-2025
22 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $52.45 · 2022: $130 · 2023: $1,064 · 2024: $365.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,418 · Education: $11.71.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,417.65 |
| Education | $11.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $317.00 | 2021-2024 | Mounjaro, Jardiance, Emgality |
| Glaxosmithkline, LLC. | $223.19 | 2022-2023 | Shingrix, Trelegy Ellipta, Arexvy |
| Novo Nordisk INC | $181.60 | 2022-2023 | Ozempic, Rybelsus |
| Janssen Pharmaceuticals, INC | $176.18 | 2023-2024 | Spravato |
| Pfizer INC. | $168.02 | 2022-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $68.56 | 2023-2024 | Jardiance, Tradjenta, Synjardy |
| Abbvie INC. | $42.33 | 2024 | |
| Exact Sciences Corporation | $41.78 | 2023-2024 | Cologuard Collection Kit |
| Biohaven Pharmaceutical Holding Company LTD. | $40.88 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $40.54 | 2023 | Trintellix |
| Amgen INC. | $37.90 | 2023-2024 | Repatha, Otezla |
| Idorsia Pharmaceuticals US INC | $35.61 | 2023 | Quviviq |
| Dynavax Technologies Corporation | $33.12 | 2024 | Heplisav-B |
| Merck Sharp & Dohme LLC | $32.52 | 2023 | Dificid, Steglatro, Belsomra |
| Abbott Laboratories | $32.23 | 2023 | Freestyle Libre |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $22.97 | 2024 | Rexulti |
| Inspire Medical Systems, INC. | $19.47 | 2023 | Inspire |
| Medtronic, INC. | $16.60 | 2023 | Minimed 770g |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $15.52 | 2023 | Xifaxan |
| Astrazeneca Pharmaceuticals LP | $14.06 | 2022 | |
| Sanofi-Aventis U.S. LLC | $13.45 | 2023 | |
| Dexcom, INC. | $13.16 | 2023 | Dexcom G6 Transmitter |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Picklesimer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.